Human Hemin Orphan Europe (Human Hemin)

Human Hemin Orphan Europe is indicated for the management of acute hepatic porphyrias, particularly acute intermittent porphyria, where it helps control metabolic crises. It is administered intravenously under hospital conditions to patients who require rapid reduction of toxic porphyrin precursors.

• Reduces accumulation of aminolevulinic acid and porphobilinogen during acute attacks.
• Helps restore normal heme synthesis pathways in hepatic tissue.
• May be used as adjunct therapy when conventional treatments are insufficient.
• Provides a source of exogenous heme to down‑regulate aminolevulinic acid synthase activity.
• Supports stabilization of neurological and gastrointestinal symptoms associated with porphyria crises.

• Human hemin delivered intravenously supplies exogenous heme that binds to the regulatory site of aminolevulinic acid synthase (ALAS1) in hepatic cells. This feedback inhibition down‑regulates ALAS1 transcription and enzymatic activity, decreasing the synthesis of aminolevulinic acid and downstream porphyrin intermediates. By restoring heme homeostasis, the drug reduces the buildup of neurotoxic precursors that trigger acute porphyria attacks. The effect is rapid, typically observable within hours after infusion.

Human Hemin Orphan Europe may be associated with adverse reactions following intravenous administration. Reported events vary in frequency and severity. Patients should be monitored during and after infusion to detect any emerging symptoms promptly.

Common

• Mild pain, redness, or swelling at the injection site.
• Transient fever, chills, or rigors occurring shortly after infusion.
• Nausea, occasional vomiting, or mild abdominal discomfort.
• Headache, dizziness, or a feeling of light‑headedness.

Serious

• Allergic reactions such as rash, pruritus, angio‑edema, or anaphylaxis.
• Hemolytic anemia, particularly in individuals with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency.
• Acute kidney injury manifested by reduced urine output or elevated creatinine.
• Severe hypotension, cardiovascular collapse, or arrhythmias requiring emergency intervention.

When using Human Hemin Orphan Europe, several precautions should be observed to minimize risk and ensure safe administration.

• Verify patient identity and indication before preparation.
• Assess for G6PD deficiency, as hemolysis risk is increased.
• Monitor vital signs and infusion site throughout the administration.
• Perform baseline and periodic liver and renal function tests.
• Avoid rapid infusion rates; administer according to recommended infusion guidelines.
• Ensure availability of emergency equipment for managing anaphylactic reactions.
• Document all administered doses and any adverse events in the patient’s medical record.

Human Hemin Orphan Europe can interact with other medicines; awareness of potential interactions helps guide safe co‑administration.

Avoid

• Concomitant use with strong oxidizing agents that may exacerbate oxidative stress.
• Simultaneous administration with drugs that induce hepatic ALAS1 expression, such as certain anticonvulsants.

Use with caution

• Anticoagulants, because hemin may affect coagulation parameters.
• Iron‑containing preparations, which could alter heme metabolism.
• Renal‑excreting drugs, requiring monitoring of renal function.
• Photosensitizing agents, as hemin may increase photosensitivity risk.
• Cytotoxic chemotherapy, because overlapping toxicities on liver function may occur.

Review the patient’s medication list and adjust therapy as needed before initiating treatment.